Table 1. Baseline demographics of melioidosis patients on diabetic therapy.

	Sulphonylurea (N = 44)	Without Sulphonylurea (N = 30)	P value
Gender
Male	39 (88.6%)	24 (80.0%)	0.336
Female	5 (11.4%)	6 (20.0%)
Median age	58.2	56.5	0.536
Immunocompromised state	2 (4.5%)	4 (13.3%)	0.215
Statin use	22 (50.0%)	10 (33.3%)	0.155
HbA1c#	9.00±2.30	9.59±2.64	0.353
Serum creatinine (µmol/L)	182±200	201±281	0.750
Bp culture positive*	34 (77.3%)	26 (86.7%)	0.377
Concurrent diabetic medication
Metformin	23 (52.3%)	14 (46.7%)	0.848
Insulin	3 (6.8%)	18 (60.0%)	0.001
Thiazolidinedione	1 (2.3%)	2 (6.7%)	0.562
α-glucosidase inhibitor	9 (20.5%)	0 (0%)	0.010
Complications
Hypotension (inotropes)	13 (29.5%)	1 (3.3%)	0.005
Intubation	9 (20.5%)	2 (6.7%)	0.182
Renal Failure	8 (18.2%)	2 (6.7%)	0.187
Septicaemia	9 (20.5%)	3 (10.0%)	0.339
Any (above) complications	21 (47.7%)	5 (16.7%)	0.006
Length of stay (days)	27.7	21.5	0.168
Mortality	7 (15.9%)	1 (3.3%)	0.080

#10 (of 44) patients from the sulphonylurea group and 3 (of 30) patients from the no-sulphonylurea group had no recent HbA1c measurements available.

* Burkholderia pseudomallei culture positive. Other cases were diagnosed by positive melioidosis serology >1/64 titres.